News

New products from Abcam Biochemicals will support research into neurodegeneration and drug addiction.

A total of 11 centers now funded for up to five years.

Computer modeling may resolve conflicting results and offer hints for new drug-design strategies.

By genome-wide mapping of the Polycomb Repressive Complex 2 (PRC2)-signature histone mark, H3K27me3, in DNA methylation-deficient mouse somatic cells, the Meehan lab shows that loss of DNA methylation is coincident with widespread H3K27me3 redistribution.

UCI study also identifies possible gene target linked to cognitive disabilities.

Researchers found that people with high levels of antibodies to five common infections in their blood, previously shown to be associated with increased risk of cardiovascular disease, also are associated with an increased risk of cognitive decline.

Findings provide additional support for strategies to fight Alzheimer’s disease.

Picower Institute neuroscientists use single dose of experimental drug; could prove promising for treatment of autism symptoms.

Researchers will be able to access samples from more than 7,000 donated human brains to help study major brain diseases, thanks to a new on-line database, launched by the MRC.

A multicenter team of researchers has developed biodegradable nanoparticles that are capable of delivering inflammation-resolving drugs to sites of tissue injury.